Journal article
Differentiation of Prior SARS-CoV-2 Infection and Postacute Sequelae by Standard Clinical Laboratory Measurements in the RECOVER Cohort
Annals of internal medicine, Vol.177(9), pp.1209-1221
09/01/2024
DOI: 10.7326/M24-0737
PMID: 39133923
Abstract
There are currently no validated clinical biomarkers of postacute sequelae of SARS-CoV-2 infection (PASC).
To investigate clinical laboratory markers of SARS-CoV-2 and PASC.
Propensity score-weighted linear regression models were fitted to evaluate differences in mean laboratory measures by prior infection and PASC index (≥12 vs. 0). (ClinicalTrials.gov: NCT05172024).
83 enrolling sites.
RECOVER-Adult cohort participants with or without SARS-CoV-2 infection with a study visit and laboratory measures 6 months after the index date (or at enrollment if >6 months after the index date). Participants were excluded if the 6-month visit occurred within 30 days of reinfection.
Participants completed questionnaires and standard clinical laboratory tests.
Among 10 094 participants, 8746 had prior SARS-CoV-2 infection, 1348 were uninfected, 1880 had a PASC index of 12 or higher, and 3351 had a PASC index of zero. After propensity score adjustment, participants with prior infection had a lower mean platelet count (265.9 × 10
cells/L [95% CI, 264.5 to 267.4 × 10
cells/L]) than participants without known prior infection (275.2 × 10
cells/L [CI, 268.5 to 282.0 × 10
cells/L]), as well as higher mean hemoglobin A
(HbA
) level (5.58% [CI, 5.56% to 5.60%] vs. 5.46% [CI, 5.40% to 5.51%]) and urinary albumin-creatinine ratio (81.9 mg/g [CI, 67.5 to 96.2 mg/g] vs. 43.0 mg/g [CI, 25.4 to 60.6 mg/g]), although differences were of modest clinical significance. The difference in HbA
levels was attenuated after participants with preexisting diabetes were excluded. Among participants with prior infection, no meaningful differences in mean laboratory values were found between those with a PASC index of 12 or higher and those with a PASC index of zero.
Whether differences in laboratory markers represent consequences of or risk factors for SARS-CoV-2 infection could not be determined.
Overall, no evidence was found that any of the 25 routine clinical laboratory values assessed in this study could serve as a clinically useful biomarker of PASC.
National Institutes of Health.
Details
- Title: Subtitle
- Differentiation of Prior SARS-CoV-2 Infection and Postacute Sequelae by Standard Clinical Laboratory Measurements in the RECOVER Cohort
- Creators
- Kristine M Erlandson - University of Colorado AnschutzLinda N Geng - Stanford UniversityCaitlin A Selvaggi - Massachusetts General HospitalTanayott Thaweethai - Massachusetts General HospitalPeter Chen - Cedars-Sinai Medical CenterNathan B Erdmann - University of Alabama at BirminghamJason D Goldman - Swedish Medical CenterTimothy J Henrich - University of California, San FranciscoMady Hornig - Columbia UniversityElizabeth W Karlson - Brigham and Women's HospitalStuart D Katz - New York UniversityC Kim - RECOVER Initiative, New York, New York (C.K., R.L.)Sushma K Cribbs - Emory UniversityAdeyinka O Laiyemo - Howard UniversityRebecca Letts - University of Nebraska Medical CenterJanet Y Lin - Mount Sinai HospitalJai Marathe - Boston UniversitySairam Parthasarathy - University of ArizonaThomas F Patterson - The University of Texas at San Antonio Health Science CenterBrittany D Taylor - Boston Medical CenterElizabeth R Duffy - Boston Medical CenterMonika Haack - Beth Israel Deaconess Medical CenterBoris Julg - Ragon Institute of MGH, MIT and HarvardGabrielle Maranga - New York UniversityCarla Hernandez - Case Western Reserve UniversityNora G Singer - Grady Memorial HospitalJenny Han - Grady Memorial HospitalPriscilla Pemu - Morehouse School of MedicineHassan Brim - Howard UniversityHassan Ashktorab - Howard UniversityAlexander W Charney - Icahn School of Medicine at Mount SinaiJuan Wisnivesky - Icahn School of Medicine at Mount SinaiJenny J Lin - Mount Sinai HospitalHelen Y Chu - University of WashingtonMinjoung Go - Stanford MedicineUpinder Singh - University of Alabama at BirminghamEmily B Levitan - University of Alabama at BirminghamPaul A Goepfert - University of Alabama at BirminghamJanko Ž Nikolich - University of ArizonaHarvey Hsu - University of California, San FranciscoMichael J Peluso - University of California, San FranciscoJ Daniel Kelly - University of California, San FranciscoMegumi J Okumura - University of California, San FranciscoValerie J Flaherman - University of California, San FranciscoJohn G Quigley - University of Illinois ChicagoJerry A Krishnan - University of Illinois ChicagoMary Beth Scholand - University of UtahRachel Hess - University of UtahTorri D Metz - University of UtahMaged M Costantine - The Ohio State UniversityDwight J Rouse - Brown UniversityBarbara S Taylor - The University of Texas at San Antonio Health Science CenterMark P Goldberg - The University of Texas at San Antonio Health Science CenterGailen D Marshall - University of Mississippi Medical CenterJeremy Wood - University of KentuckyDavid Warren - University of Nebraska Medical CenterLeora Horwitz - New York UniversityAndrea S Foulkes - Massachusetts General HospitalGrace A McComsey - Case Western Reserve UniversityRECOVER-Adult Cohort
- Resource Type
- Journal article
- Publication Details
- Annals of internal medicine, Vol.177(9), pp.1209-1221
- DOI
- 10.7326/M24-0737
- PMID
- 39133923
- NLM abbreviation
- Ann Intern Med
- ISSN
- 0003-4819
- eISSN
- 1539-3704
- Grant note
- OT2 HL161841 / NHLBI NIH HHS UM1 TR004409 / NCATS NIH HHS K24 AA022523 / NIAAA NIH HHS UM1 TR004528 / NCATS NIH HHS OT2 HL161847 / NHLBI NIH HHS R01 HL151508 / NHLBI NIH HHS R01 HL162373 / NHLBI NIH HHS OT2 HL156812 / NHLBI NIH HHS
- Language
- English
- Date published
- 09/01/2024
- Academic Unit
- Internal Medicine
- Record Identifier
- 9985244552802771
Metrics
1 Record Views